Search Clinical Trials in the EU

Duration

>20 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

61-80 of 140 trials

Metastatic Uveal Melanoma: Tebentafusp Treatment

We are studying the effects of tebentafusp in patients with metastatic uveal melanoma that has spread to the liver. The goal is to see if it can help achieve complete responses and improve disease control.

Uveal Melanoma>2 yearsEfficacy phase (II)>20 visits No Placebo Standard MedicinesOncology

Pulmonary Arterial Hypertension: Sotatercept Study

We are evaluating the long-term safety of sotatercept for adults with pulmonary arterial hypertension already on treatment. This study will help us understand how well it works when added to existing therapies.

Pulmonary Arterial Hypertension>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteCardiology

Extrahepatic Cholangiocarcinoma: Durvalumab with Radiofrequency Ablation

We are studying a new treatment combining durvalumab and radiofrequency ablation for patients with bile duct cancer. The goal is to see if this combination improves effectiveness and safety compared to standard therapies.

Extrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)>20 visits No Placebo Standard MedicinesGastroenterologyOncology

Acute Myeloid Leukemia: CD19 CAR-T Cell Therapy

We are studying the safety of a new CAR-T cell treatment for patients with refractory acute myeloid leukemia. This trial aims to see how well the treatment works and how long the CAR-T cells last in the body.

Recurrent Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)>20 visits No Placebo Investigational MedicinesHematologyOncology

Non-Small Cell Lung Cancer: RMC-6236 with Pembrolizumab

We are studying a new treatment combining RMC-6236 and pembrolizumab for patients with advanced RAS-mutated non-small cell lung cancer. The goal is to evaluate its safety and potential effectiveness, with or without chemotherapy.

Non-small Cell Lung CancerSafety phase (I)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncologyPulmonology

Advanced Solid Tumors: BI-1206 with Pembrolizumab

We are studying a new treatment combining BI-1206 and pembrolizumab for patients with advanced solid tumors. This trial aims to find a safe dose and understand how well this combination works for those with specific types of cancer.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementInternal MedicineOncology

Multiple Myeloma: Mezigdomide vs. Pomalidomide

We are studying whether a new drug, mezigdomide, combined with bortezomib and dexamethasone, is more effective than pomalidomide with the same drugs for patients with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple Myeloma≤3 monthsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementHematologyOncology

Mantle Cell Lymphoma: Zanubrutinib with Rituximab

We are comparing a new treatment combining Zanubrutinib and Rituximab to standard therapy for patients with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see which treatment works better and is safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visits No Placebo Standard Medicines Cost ReimbursementHematologyOncology

Difelikefalin for Itching in Adolescents on Hemodialysis

We are studying whether difelikefalin is safe for adolescents aged 12 to 17 who have moderate-to-severe itching related to long-term kidney disease. This trial aims to help improve care for young patients undergoing hemodialysis.

Generalized ItchingChronic Kidney Diseases3-6 monthsEfficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteDermatologyNephrologyPediatrics

Chronic Graft-Versus-Host Disease: Axatilimab Treatment

We are studying whether axatilimab, combined with corticosteroids, helps improve symptoms in patients with moderate to severe chronic graft-versus-host disease. This trial compares its effects to a placebo.

Chronic Graft-Versus-Host DiseaseConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementHematologyInfectious Diseases

Advanced Solid Tumors: DF6002 Treatment Study

We are investigating the safety and effectiveness of DF6002, alone and with Nivolumab, for patients with advanced solid tumors. This study aims to find the best dose and understand how well the treatment works.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visits No Placebo Investigational MedicinesOncology

Acute Myeloid Leukemia: Venetoclax and Azacitidine Treatment

We are studying whether a combination of venetoclax and azacitidine can help clear residual disease in AML patients before a stem cell transplant. This trial also looks at the safety and effectiveness of this treatment approach.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visits No Placebo Standard MedicinesHematologyOncology

Follicular Lymphoma: Tazemetostat with Lenalidomide and Rituximab

We are studying the safety and effectiveness of tazemetostat combined with lenalidomide and rituximab in adults with relapsed or refractory follicular lymphoma. This trial compares the new treatment to a placebo to see how well it works.

Relapsed/Refractory Follicular Lymphoma>2 yearsConfirmation phase (III)>20 visits Investigational MedicinesHematologyOncology

DAY101 for Pediatric Brain Cancer and Solid Tumors

We are studying the effects of DAY101 in children aged 6 months to 25 years with low-grade glioma or advanced solid tumors. The goal is to see if it helps shrink tumors and to assess its safety.

Malignant Glioma>2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncologyPediatrics

Dementia with Lewy Bodies: Ambroxol Study

We are investigating whether Ambroxol can improve cognitive and functional abilities in people with early Dementia with Lewy Bodies. The study also looks at its effects on sleep disturbances and other related symptoms.

Dementia with Lewy Bodies1-2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access Standard MedicinesNeurologyPsychiatry

Hidradenitis Suppurativa: Lutikizumab Study

We are evaluating the effectiveness and safety of lutikizumab for treating moderate to severe hidradenitis suppurativa in adults and adolescents. This study compares lutikizumab to a placebo to see how well it works.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementDermatology

Mucopolysaccharidosis Type II: DNL310 vs Idursulfase

We are studying a new treatment, DNL310, for children and young adults with Mucopolysaccharidosis Type II to see if it works better than the current treatment, Idursulfase, in improving brain and physical health.

Hunter's Syndrome>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementHematologyNeurology

Advanced Prostate Cancer: Debio 4228 Study

We are testing a new medication, Debio 4228, to see if it effectively lowers hormone levels in men with advanced prostate cancer. The study will also look at how well the medication is tolerated and its safety profile.

Advanced Prostate Cancer6-12 monthsEfficacy phase (II)>20 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncologyUrology

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy: ION-682884 Study

We are assessing the long-term safety and effectiveness of ION-682884 in patients with hereditary transthyretin-mediated amyloid polyneuropathy. This study aims to understand how well the treatment works over time.

Familial Amyloid PolyneuropathyConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteInternal MedicineNeurology

Breast Cancer: Abemaciclib with Endocrine Therapy

We are studying a combination of Abemaciclib and endocrine therapy for patients with advanced hormone receptor positive HER2 negative breast cancer. The trial focuses on how well this treatment works and how we can manage side effects using digital tools.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)>20 visits Post-Trial Drug Access No Placebo Standard MedicinesOncology

Search Clinical Trials in the European Union